Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Cash: 2014-2025

Historic Change in Cash for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to -$76.8 million.

  • ImmunityBio's Change in Cash fell 323.45% to -$76.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 22.78%. This contributed to the annual value of -$121.9 million for FY2024, which is 175.78% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Change in Cash is -$76.8 million, which was down 199.75% from $77.0 million recorded in Q2 2025.
  • ImmunityBio's 5-year Change in Cash high stood at $134.5 million for Q3 2023, and its period low was -$144.7 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Cash was -$16.2 million (2023), whereas its average is -$4.0 million.
  • In the last 5 years, ImmunityBio's Change in Cash tumbled by 1,582.14% in 2022 and then skyrocketed by 18,127.08% in 2023.
  • ImmunityBio's Change in Cash (Quarterly) stood at $116.6 million in 2021, then slumped by 99.59% to $480,000 in 2022, then spiked by 18,127.08% to $87.5 million in 2023, then plummeted by 63.87% to $31.6 million in 2024, then slumped by 323.45% to -$76.8 million in 2025.
  • Its Change in Cash was -$76.8 million in Q3 2025, compared to $77.0 million in Q2 2025 and -$82.8 million in Q1 2025.